We are live on ! Find out more

Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$121B
$121B $477.10 0.95%
REGN icon
2
Regeneron Pharmaceuticals
REGN
$78.5B
$78.5B $762.63 3.29%
ARGX icon
3
argenx
ARGX
$53.4B
$53.4B $853.82 2.15%
RVMD icon
4
Revolution Medicines
RVMD
$39.9B
$39.9B $187.53 2.41%
ONC
5
BeOne Medicines Ltd
ONC
$32.8B
$32.8B $316.01 1.88%
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$27.5B
$27.5B $205.52 0.02%
RPRX icon
7
Royalty Pharma
RPRX
$25.9B
$25.9B $58.43 1%
ROIV icon
8
Roivant Sciences
ROIV
$24.5B
$24.5B $33.91 1.77%
INCY icon
9
Incyte
INCY
$24.2B
$24.2B $119.52 2.82%
BNTX icon
10
BioNTech
BNTX
$22.9B
$22.9B $90.58 2.44%
MRNA icon
11
Moderna
MRNA
$21.8B
$21.8B $54.82 5.35%
INSM icon
12
Insmed
INSM
$21.4B
$21.4B $98.60 2.85%
GMAB icon
13
Genmab
GMAB
$17.7B
$17.7B $28.87 0.8%
ASND icon
14
Ascendis Pharma A/S
ASND
$16B
$16B $243.91 2.85%
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$15.9B
$15.9B $252.86 2.14%
BBIO icon
16
BridgeBio Pharma
BBIO
$15.7B
$15.7B $80.09 2.5%
EXEL icon
17
Exelixis
EXEL
$13.3B
$13.3B $53.03 5.25%
CORT icon
18
Corcept Therapeutics
CORT
$12.4B
$12.4B $114.49 3.24%
ARWR icon
19
Arrowhead Research
ARWR
$11.9B
$11.9B $84.65 3.06%
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$11.6B
$11.6B $60.02 0.92%
TECH icon
21
Bio-Techne
TECH
$11.2B
$11.2B $72.09 0.08%
AXSM icon
22
Axsome Therapeutics
AXSM
$11.2B
$11.2B $217.99 7.1%
ABVX
23
Abivax
ABVX
$10.9B
$10.9B $124.92 0.47%
MDGL icon
24
Madrigal Pharmaceuticals
MDGL
$10.8B
$10.8B $467.32 5.23%
CYTK icon
25
Cytokinetics
CYTK
$10.5B
$10.5B $77.13 4.09%
1
2 3 4 5

Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 566 Biotechnology industry stocks tracked by Wall St. Rank, worth a combined $1.2T.

The largest by market cap are Vertex Pharmaceuticals (VRTX) at $121B, Regeneron Pharmaceuticals (REGN) at $78.5B and argenx (ARGX) at $53.4B.

Among institutional investors, Atrium Therapeutics (RNA) drew the most net new fund positions in Q1 2026: 162 funds opened new positions.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.